NewAmsterdam Pharma Company NAMS Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's accrued expenses and other liabilities?
- NewAmsterdam Pharma Company (NAMS) reported accrued expenses and other liabilities of -$10.33M in Q1 2026.
- How has NewAmsterdam Pharma Company's accrued expenses and other liabilities changed year-over-year?
- NewAmsterdam Pharma Company's accrued expenses and other liabilities decreased by 108.6% year-over-year, from -$4.95M to -$10.33M.